 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Todd Bull and David Badesch.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.052 |
|
|
|
-
Bull T, Badesch DB. Sildenafil for COPD: a randomized crossover trial. COPD. 2012 Jun; 9(3):211-2.
Score: 0.438
-
Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am. 2005 Aug; 31(3):451-64, vi.
Score: 0.273
-
Bull TM, Cool CD, Serls AE, Rai PR, Parr J, Neid JM, Geraci MW, Campbell TB, Voelkel NF, Badesch DB. Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8. Eur Respir J. 2003 Sep; 22(3):403-7.
Score: 0.239
-
Lee MH, Doran J, Bang TJ, Hohsfield R, Hountras P, Boddie G, Wagh MS, Badesch D, Bull TM. Pulmonary Arterial Hypertension and Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Novel Association? Chest. 2021 12; 160(6):2260-2265.
Score: 0.206
-
Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, Maloney J, De Marco T, Ivy D, Thenappan T, Sager JS, Ryan JJ, Mazimba S, Hirsch R, Chakinala M, Shlobin O, Lammi M, Zwicke D, Robinson J, Benza RL, Klinger J, Grinnan D, Mathai S, Badesch D. Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. Pulm Circ. 2020 Oct-Dec; 10(4):2045894020964342.
Score: 0.197
-
Hunt JM, Risbano MG, Messenger JC, Carroll J, Badesch D, Lowes BD, Casserly IP, Kay J, Bull TM. Timed response to inhaled nitric oxide in pulmonary hypertension. Pulm Circ. 2014 Mar; 4(1):103-9.
Score: 0.124
-
McCormick A, Krishnan A, Badesch D, Benza RL, Bull TM, De Marco T, Feldman J, Hemnes AR, Hirsch R, Horn E, Kennedy J, Mathai SC, McConnell W, Pugliese SC, Sager JS, Shlobin OA, Simon MA, Lammi MR. Pulmonary artery compliance in different forms of pulmonary hypertension. Heart. 2023 06 26; 109(14):1098-1105.
Score: 0.059
-
Mayer M, Badesch DB, Nielsen KH, Kawut S, Bull T, Ryan JJ, Sager J, Mazimba S, Hemnes A, Klinger J, Runo J, McConnell JW, De Marco T, Chakinala MM, Yung D, Elwing J, Kaplan A, Argula R, Pomponio R, Peterson R, Hountras P. Impact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry. Pulm Circ. 2023 Apr; 13(2):e12233.
Score: 0.058
-
DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ. Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry. Pulm Circ. 2022 Oct; 12(4):e12172.
Score: 0.057
-
Grinnan D, Kang L, DeWilde C, Badesch D, Benza R, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Klinger J, McConnell J, Rosenzweig EB, Sager J, Shlobin O, Zamanian R. Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation. Pulm Circ. 2022 Jul; 12(3):e12120.
Score: 0.055
-
Hill NS, Feldman JP, Sahay S, Benza RL, Preston IR, Badesch D, Frantz RP, Patel S, Galloway A, Bull TM. INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulm Circ. 2022 Jul; 12(3):e12119.
Score: 0.055
-
Minhas J, Narasimmal SP, Bull TM, De Marco T, Mc Connell JW, Lammi MR, Thenappan T, Feldman JP, Sager JS, Badesch DB, Ryan JJ, Grinnan DC, Zwicke D, Horn EM, Elwing JM, Moss JE, Eggert M, Shlobin OA, Frantz RP, Bartolome SD, Mathai SC, Mazimba S, Pugliese SC, Al-Naamani N. Corrigendum for health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: And analysis from the Pulmonary Hypertension Association Registry. Pulm Circ. 2022 Apr; 12(2):e12085.
Score: 0.055
-
Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022 05 03; 11(9):e024969.
Score: 0.054
-
DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ. Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulm Circ. 2021 Jul-Sep; 11(3):20458940211020913.
Score: 0.051
-
Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J. 2021 02; 57(2).
Score: 0.050
-
Naeije R, Saggar R, Badesch D, Rajagopalan S, Gargani L, Rischard F, Ferrara F, Marra AM, D' Alto M, Bull TM, Saggar R, Gr?nig E, Bossone E. Exercise-Induced Pulmonary Hypertension: Translating Pathophysiological Concepts Into Clinical Practice. Chest. 2018 07; 154(1):10-15.
Score: 0.041
-
Bansal S, Badesch D, Bull T, Schrier RW. Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study. Contemp Clin Trials. 2009 Sep; 30(5):392-9.
Score: 0.022
-
Fagan KA, Bull TM, Badesch DB, Voelkel NF. Metastatic cancer while receiving continuous prostacyclin therapy. Chest. 2005 Dec; 128(6 Suppl):619S-620S.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|